SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AND THE RISK OF HEPATOCELLULAR CARCINOMA AMONG PATIENTS WITH TYPE 2 DIABETES, METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE, AND OBESITY: A LARGE POPULATION-BASED COHORT STUDY

被引:0
|
作者
Mukherjee, Arunkumar Krishnan Diptasree [1 ]
Abaalkhail, Faisal [2 ]
Althwanay, Aldanah [3 ]
Woreta, Tinsay [4 ]
Alqahtani, Saleh [4 ]
机构
[1] Apex Inst Med Sci, Kolkata, India
[2] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia
[3] Univ Maryland, Med Ctr, College Pk, MD USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
1170
引用
收藏
页码:S891 / S891
页数:1
相关论文
共 50 条
  • [1] Sodium-glucose cotransporter-2 inhibitors and risk of hepatocellular carcinoma among patients with type 2 diabetes: A population-based cohort study
    Bea, Sungho
    Jeong, Han Eol
    Noh, Yunha
    Park, Sohee
    Sinn, Dong Hyun
    Kim, Jae Hyeon
    Yu, Oriana H. Y.
    Azoulay, Laurent
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 57 - 58
  • [2] Sodium-glucose Cotransporter-2 Inhibitors and Risk of Hepatocellular Carcinoma Among Patients With Type 2 Diabetes
    Bea, Sungho
    Jeong, Han Eol
    Kim, Jae Hyeon
    Yu, Oriana Hy
    Azoulay, Laurent
    Shin, Ju-Young
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (13) : 3451 - +
  • [3] Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study
    Eroglu, Talip E.
    Coronel, Ruben
    Souverein, Patrick C.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (04) : 289 - 295
  • [4] Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes A Population-Based Cohort Study
    Fralick, Michael
    Chen, Sarah K.
    Patorno, Elisabetta
    Kim, Seoyoung C.
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (03) : 186 - +
  • [5] Patterns and Patients' Characteristics Associated With Use of Sodium-Glucose Cotransporter-2 Inhibitors Among Adults With Type 2 Diabetes: A Population-based Cohort Study
    Campbell, Dennis B.
    Campbell, David J. T.
    Au, Flora
    Beall, Reed F.
    Ronksley, Paul E.
    Chew, Derek S.
    Ogundeji, Yewande
    Manns, Braden J.
    Hemmelgarn, Brenda R.
    Tonelli, Marcello
    Quinn, Amity E.
    CANADIAN JOURNAL OF DIABETES, 2023, 47 (01) : 58 - +
  • [6] Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study
    Fu, Edouard L. L.
    D'Andrea, Elvira
    Wexler, Deborah J.
    Patorno, Elisabetta
    Paik, Julie M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (05): : 592 - 601
  • [7] Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
    Mao, Xianhua
    Zhang, Xinrong
    Kam, Leslie
    Chien, Nicholas
    Lai, Rongtao
    Cheung, Ka-Shing
    Yuen, Man-Fung
    Cheung, Ramsey
    Seto, Wai-Kay
    Nguyen, Mindie H.
    GUT, 2024, 73 (12) : 2054 - 2061
  • [8] Use of sodium-glucose cotransporter-2 inhibitors and risk of dementia: A population-based cohort study
    Zhuo, Lin
    Zhang, Baixue
    Yin, Yueqi
    Sun, Yexiang
    Shen, Peng
    Jiang, Zhiqin
    Zhan, Siyan
    Zhao, Houyu
    DIABETES OBESITY & METABOLISM, 2025, 27 (05): : 2430 - 2441
  • [9] Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study
    Hong, Bin
    Bea, Sungho
    Ko, Hwa Yeon
    Kim, Woo Jung
    Cho, Young Min
    Shin, Ju-Young
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (10) : 1319 - 1329
  • [10] Sodium-glucose cotransporter-2 inhibitors and risk of urolithiasis in patients with type 2 diabetes: A population-based active comparator new user cohort study
    Kristensen, Kasper Bruun
    Henriksen, Daniel Pilsgaard
    Hallas, Jesper
    Lund, Lars Christian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 108 - 109